ReproCell Stock

ReproCell EV/Revenue

The EV/Revenue (Enterprise Value to Revenue) of ReproCell (4978.T) as of Aug 6, 2026 is 3.86. In the previous year, EV/Revenue (Enterprise Value to Revenue) was 3.66 — a change of 5.56% (higher).

EV/Revenue

3.86

YoY

5.56%

Last updated:

EV/Revenue (Enterprise Value to Revenue) of ReproCell is 2026 3.86 . EV/Revenue (Enterprise Value to Revenue) of ReproCell was 2025 3.66 . It decreases by 5.56% higher compared to the previous year.
Access this data via the Eulerpool API

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

EV/Revenue (Enterprise Value to Revenue) of ReproCell is 3.86 in 2026.

EV/Revenue (Enterprise Value to Revenue) of ReproCell changed from 3.66 to 3.86, representing a 5.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/Revenue (Enterprise Value to Revenue) ReproCell since 2006 – with annual values, charts, and detailed analysis.

The EV/Revenue ratio compares a company's enterprise value to its total revenue. It is particularly useful for valuing high-growth companies that may not yet be profitable.

To evaluate EV/Revenue (Enterprise Value to Revenue)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/Revenue (Enterprise Value to Revenue).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/Revenue (Enterprise Value to Revenue)'s ReproCell with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — ReproCell

All Key Metrics — ReproCell